Discovery of Novel Peptide Antagonists Targeting GPR55 for Liver Inflammation and Fibrosis
Journal of Medicinal Chemistry · 25.07.2024 · 67 (14) · 12085-12098
DOI: 10.1021/acs.jmedchem.4c00834 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 11.07.2024. Verfasst von Zihan Shi und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, C…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Receptors, G-Protein-Coupled, Receptors, Cannabinoid. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Lanzhou University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Liver fibrosis is a condition characterized by aberrant proliferation of connective tissue in the liver resulting from diverse etiological factors. G protein-coupled receptor GPR55 has recently been identified as a regulator of liver diseases. Herein, we report the discovery of a cyclic peptide P1-1 that antagonizes GPR55 and suppresses collagen secretion in hepatic stellate cells. The alanine scanning and docking study was carried out to predict the binding mode and allowed for further structural optimization of peptide antagonists for GPR55. The subsequent in vivo study demonstrated that P1-1 ameliorates CCl4-induce and MCD-diet-induce acute liver inflammation and fibrosis. Further study indicates that P1-1 reduces reactive oxygen species (ROS) production, attenuates ER stress, and inhibits mitochondria-associated hepatocyte apoptosis. In this work, we provided the first successful example of antagonizing GPR55 for liver inflammation and fibrosis, which validates GPR55 as a promising target for the treatment of liver fibrosis and affords a high-potent GPR55 antagonist P1-1 as a potential therapeutic candidate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
- Shenzhen Turier Biotech. Co. Ltd, Shenzhen 518000, China.
ORCID-Profile: Albert S C Chan, Xianxing Jiang
Förderung
- Lanzhou University
- National Natural Science Foundation of China
Zitieren
APA
Shi, Z., Liu, X., Wu, S., Song, N., Tang, Q., Li, H., Luo, S., Chan, A. S. C., Cai, X., Liu, H., & Jiang, X. (2024). Discovery of Novel Peptide Antagonists Targeting GPR55 for Liver Inflammation and Fibrosis. Journal of Medicinal Chemistry, 67(14), 12085-12098. https://doi.org/10.1021/acs.jmedchem.4c00834
Vancouver
Shi Z, Liu X, Wu S, Song N, Tang Q, Li H, et al. Discovery of Novel Peptide Antagonists Targeting GPR55 for Liver Inflammation and Fibrosis. Journal of Medicinal Chemistry. 2024;67(14):12085-12098. doi:10.1021/acs.jmedchem.4c00834
BibTeX
@article{Shi2024,
author = {Shi, Zihan and Liu, Xianyan and Wu, Shuohan and Song, Nazi and Tang, Qinglin and Li, Haonan and Luo, Suijia and Chan, Albert S C and Cai, Xiaoqing and Liu, Han and Jiang, Xianxing},
title = {Discovery of Novel Peptide Antagonists Targeting GPR55 for Liver Inflammation and Fibrosis},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {14},
pages = {12085--12098},
doi = {10.1021/acs.jmedchem.4c00834}
}
EUVIMED